Recruiting

Calcium Chloride & Carbetocin

Sponsor:

Samuel Lunenfeld Research Institute, Mount Sinai Hospital

Code:

NCT07187544

Conditions

Postpartum Hemorrhage (Primary)

Eligibility Criteria

Sex: Female

Age: 18 - 45

Healthy Volunteers: Accepted

Interventions

Calcium Chloride

Placebo

Carbetocin

Study Details

Brief summary:

Postpartum hemorrhage (PPH) is a leading cause of maternal mortality, and its severity has been increasing globally, including in high-income countries. The most common cause of PPH is uterine atony occurring in about 70% of cases. Uterotonic agents, like oxytocin, are key in managing the third stage of labour to prevent PPH. Oxytocin is a short-acting medication and requires frequent dosing, however, carbetocin, a longer-acting analogue that can be administered as a single dose, provides sustained uterotonic activity. Calcium chloride is a readily available, inexpensive medication that has been studied as an adjunct to primary uterotonics due to its role in uterine contractility. A randomized trial found no overall reduction in blood loss with calcium chloride and oxytocin, but a subgroup analysis suggested it may reduce bleeding in cases of uterine atony. This study was conducted in the US where carbetocin is not readily available. The investigators propose a double-blind randomized trial investigating if co-administering calcium chloride with carbetocin during scheduled cesarean deliveries reduces PPH secondary to uterine atony.

Conditions

Postpartum Hemorrhage (Primary)

Study ID

NCT07187544

Start date

Dec 1, 2025

Status verified date

Feb, 2026

Completion date

Dec, 2026

Anticipated

Primary completion date

Dec, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 18 - 45

Healthy Volunteers: Accepted

Inclusion Criteria:

1. Scheduled CD for patients ≥ 37 weeks excluding high risk factors for uterine atony
2. Neuraxial anesthesia as the primary anesthetic where intrathecal medications are the primary anesthetic

Exclusion Criteria:

1. Risk factors for uterine atony including:

1. Overdistended uterus due to fetal macrosomia reported on prenatal ultrasound >90th centile or > 4000 gm, multiple gestation, grand multiparity (≥5 births at ≥ 20 weeks gestation), polyhydramnios
2. History of uterine atony/PPH (documented with blood loss > 2000 ml, blood transfusion, use of surgical methods such as Bakri balloon, B-Lynch sutures, uterine artery ligation or embolization)
3. Obesity with body mass index (BMI) > 40 kg/m2
4. Placenta previa and/or placenta accreta
2. Digoxin therapy within 14 days (hypercalcemia can exacerbate digoxin toxicity)
3. Patients needing intraoperative IV ceftriaxone or tetracycline.
4. Kidney disease including Stage 3 chronic kidney disease, serum creatinine above 120 mmol/L or GFR <60 ml/min (to prevent hypercalcemia due to reduced creatinine clearance in those with impaired kidney function as calcium is renally excreted)
5. Calcium channel blockade within 24 hours (opposing effect)
6. Known history of cardiac disease including arrhythmias, ischemia, and congenital heart disease (to avoid attributing cardiac symptoms to study drugs)
7. Preexisting hypertension, preeclampsia or persistent elevated blood pressure above 160/100 mmHg requiring treatment
8. Emergency cesarean deliveries or women in labor
9. Planned general anesthetic for patients where neuraxial is contraindicated.

Study Design

Enrollment

120 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

active comparator: Calcium

Intravenous calcium chloride 10% (1g) will be administered in 100ml normal saline, over 10 minutes.

placebo comparator: Placebo

Intravenous administration of 100ml normal saline, over 10 minutes.

Interventions

Calcium Chloride

Intravenous calcium chloride 10% (1g) will be administered in 100ml normal saline, over 10 minutes.

Placebo

Intravenous administration of 100ml normal saline, over 10 minutes.

Carbetocin

50 mcg intravenous carbetocin.

Primary outcome measure

  • Uterine Tone 10 minutes [ Time Frame: 10 minutes ]

Central Contacts and Locations

Central contacts

Locations

Mount Sinai Hospital

Recruiting

Toronto, Ontario, Canada, M5G1X5

Contacts

More Information

Sponsor

Samuel Lunenfeld Research Institute, Mount Sinai Hospital

Last update posted

Apr 1, 2026

Last verified

Feb, 2026

Keywords

  • calcium
  • carbetocin
  • cesarean

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Samuel Lunenfeld Research Institute, Mount Sinai Hospital on 2026-04-01.